IMPORTANCE OF LUNG INFLAMMATION
It is well recognized that long-standing inflammation damages the lungs in children and adults with cystic fibrosis (CF), and it is no coincidence that most CF deaths are due to respiratory failure. The lung inflammation is primarily due to the host response to chronic bacterial infection, particularly with Pseudomonas aeruginosa, which calls into question the whole concept of colonization, with its implication of bacteria residing harmlessly in the body. However, it has also been suggested that inflammation may actually precede microbial infection in the CF lung, an idea based on the fact that significant inflammation has been detected in broncho-alveolar lavage (BAL) samples in which microbes (bacteria, viruses or fungi) were not isolatedl2. It is possible that in the young patients studied the infection had been eradicated but that the resultant inflammation simply persisted3. In older children, however, it is unlikely that the pathogenic bacteria are ever eradicated. In addition, using more sensitive molecular techniques for identifying bacteria, it may be that infection is going unrecognized when standard culture methods are employed4. More recently, it has been suggested that inflammation may be an integral part of the CF defect. Accumulation of faulty CFTR (CF transmembrane conductance regulator) protein in the cell endoplasmic reticulum may result in production of proinflammatory cytokines following activation of the transcription factor NFKB5. In conclusion, it seems most likely that the majority of lung inflammation is in fact secondary to recurrent bacterial or viral infections, but that there is a contribution from endogenous factors, and possibly even a reaction to the abnormal mucus lining the epithelium. It is still unexplained why the production of interleukin-10, an important anti-inflammatory cytokine, is reduced in CF epithelial cells67.
Pivotal role of the neutrophil Cytological examination of sputum or BAL fluid from a patient with CF reveals an abundance of neutrophils. It is a feature of CF that neutrophils are the predominant phagocytic cells in the lungs, rather than alveolar macrophages. An increased neutrophil cell count and raised levels of interleukin-8 In normal individuals, the epithelial surface of the lung is protected from neutrophil elastase by antiproteases22, the main two of which have several names (Box l).
a1 -antitrypsin/al -antiprotease al-antitrypsin (Cal-AT) is probably better referred to as oalantiprotease (axl-AP), but since the former term has a disease named after it, this older term is still used. It is an acute phase protein that is produced in the liver (by hepatocytes) and reaches the lungs via the plasma, where it coats the respiratory bronchioles and alveoli38. It is the main inhibitor of neutrophil elastase within the lower respiratory tract, providing more than 90% of the anti-neutrophil elastase defence39. In normal individuals, the molar quantities of the antiproteases in the respiratory epithelial lining fluid far outweigh that of neutrophil elastase, hence damage to the epithelium and local host defence is prevented22. Unfortunately, this is not the case in CF, where huge quantities of neutrophil elastase simply overwhelm the antiproteases, with molar levels of immunoreactive neutrophil elastase being 12 times higher than that of cxl-antiprotease in the sputum20. It is not a production problem, as oa -antiprotease is present in normal amounts and fully active in the serum40. Not only is alantiprotease outnumbered, but it is also inactivated in the CF airways by the proteases themselves41, since a1-antiprotease is proteolytically degraded by neutrophil elastase as soon as the molar ratio exceeds 1:1 in favour of neutrophil elastase42. In addition, cAl-antiprotease is inactivated by bacterial proteases, with P. aeruginosa elastase inactivating the antiprotease more rapidly than S. aureus proteinase38. shown to be associated with earlier onset of P. aeruginosa infection and higher serum IgG levels43 (both of which are poor prognostic signs). However, lung function did not seem to be affected, although this may have been due to the Danish policy of using regular anti-pseudomonal antibiotics. In a UK study, 20/147 unrelated CF patients were found to have al-antitrypsin deficiency phenotypes (MS, S and MZ) but this was in fact associated with significantly better lung function4. Of course, in patients with ai-antitrypsin deficiency alone, the lungs are not usually affected in childhood, emphysematous changes tend to begin in early adulthood, and are more common in smokers.
Secretory leukoprotease inhibitor Secretory leukoprotease inhibitor (SLPI) is produced by the respiratory epithelium in bronchi and bronchioles45.
However, proportionately it is the main antiprotease of the upper respiratory tract and the large airways only46. Although it has been shown to be an excellent inhibitor of neutrophil elastase, the majority (about two-thirds) of SLPI in the epithelial lining fluid is inactive47 (Table 3) . This means it is unlikely to play a significant role, compared to oi -antiprotease, in protecting the respiratory epithelium except in the upper airways where it is at its highest concentration47. The reason for this high degree of inactivation in normal individuals is not clear, the molecule is intact, not bound in a complex, and has not been exposed to neutrophil elastase or oxidants, factors that may be more relevant in CF47. Certainly bacterial proteases can inactivate SLPI, although it is much less susceptible (20-50 000-fold less) to this type of degradation than oc-antiprotease38.
Nevertheless, SLPI probably acts in conjunction with alantiprotease, but since it is a smaller molecule with a higher isoelectric point, close to that of neutrophil elastase, it might compartmentalize in a similar fashion to neutrophil elastase, thus increasing its relevance in the lungs' defence against proteases47. SLPI has other useful properties besides its antiprotease activity. Work with recombinant SLPI (rSLPI) has shown that it increases glutathione levels in lung secretions within hours of administration48. The resultant increase in lung antioxidant capacity might well prove to be important in CF, and will also help protect at-antiprotease from oxidative inactivation. In addition, SLPI may have a role as a naturally-occurring broad-spectrum antibiotic, with antiretroviral, bacteriocidal and antifungal activity49. Finally, an in vitro study has shown that when the corticosteriod fluticasone propionate was added to airway epithelial cells, there was an increase in mRNA transcript levels of SLPI within 12 h, which may be one of the antiinflammatory mechanisms of this steroid50.
CLINICAL TRIALS OF ANTIPROTEASE THERAPY
The imbalance of the neutrophil elastase-anti-neutrophil elastase system is well established by 1 year of age, allowing for many years of lung destruction22. It is likely that there would be a major impact on lung morbidity and even CF mortality if it were possible to reduce the amount of free neutrophil elastase in the lungs. Although intravenous (antipseudomonal) antibiotics do significantly reduce levels of neutrophil elastase, the effect is short-lived and a considerable amount of neutrophil elastase activity remains in the lower respiratory tract secretions21. The alternative and more logical approach is to supplement the overwhelmed antiproteases to combat the proteolytic destruction in the lungs51. In contrast to cl-antitrypsin deficiency, where intravenous replacement therapy of human plasmaderived al-antitrypsin may have some role32, this is not an option in CF40. Aside from the fact that serum activity is normal anyway in CF, frequent massive doses would be required to free the lung of elastolytic activity. It has been estimated that only 2% of infused ail-antitrypsin reaches the lungs52. Furthermore, an abstract report in which CF patients were given an intravenous infusion of ocl-antitrypsin showed elastase activity persisted for 12 h only in the respiratory epithelial lining fluid, compared to 1 week in patients with oxl-antitrypsin deficiency53.
ca -antitrypsin
A commercial preparation of ocl-antiprotease is now available, derived from pooled human plasma, called Prolastin (Bayer Corporation, Pittsburgh, USA). The problem with this form of therapy is first the limited availability, and secondly the safety concerns of using a plasma product over many years. Indeed, since 1994, Bayer Corporation has withdrawn several batches of Prolastin due to fears over possible transmission of Creutzfeldt-Jakob disease. It is probably for these reasons that a larger trial has not been carried out after the initial work.
Pharmacokinetic studies in normal volunteers showed that aerosoli7ed Prolastin gave no substantial side-effects and 36 h after a single dose, cl-antiprotease concentrations and anti-neutrophil elastase activity were still double that at baseline54. Surprisingly, this study was performed 6 years after the first trial in CF was reported55. In this initial promising study, 12 adults with CF were given nebulized Prolastin (1.5-3.0 mg/kg) twice daily for 1 week55. It suppressed neutrophil elastase in the respiratory epithelial lining fluid and reversed the inhibitory effect of epithelial lining fluid on P. aeruginosa killing by neutrophils. The treatment was well tolerated. Following on from this, a phase I study in five centres across the USA was carried out56. Twenty-two adult patients were given 100-350 mg nebulized Prolastin twice daily for 4 weeks. In all patients but one, there was a decrease in elastase activity and an increase in the capacity to inhibit added elastase in secretions recovered from the lungs. There was no change in neutrophil count nor 11-8 level in epithelial lining fluid. Five patients had moderate adverse effects possibly related to the drug (four had chest symptoms, one had joint symptoms), while one patient had severe respiratory symptoms which were probably related to the drug.
Secretory leukoprotease inhibitor
There are reasons why using SLPI may have some advantages over exogenous ai-antiprotease, and these are mainly related to its physical properties39, but recombinant SLPI (rSLPI) is also far less susceptible to degradation by bacterial proteases than cx1-antiprotease38. rSLPI is produced by Escherichia coli using a synthetic SLPI Synthetic inhaled anti-elastase drugs Another agent that has been developed is FK706. In an open-labelled pilot study, it was nebulized once or twice per day for 10 days in 16 patients64. It led to a significant reduction in sputum neutrophil elastase activity, as well as a significant reduction in plasma 11-8 and E-selectin. However, four patients withdrew, with a decrease in lung function parameters in three of them. It may simply be that a bronchodilator is required before the drug is administered, but it is not yet clear whether the pharmaceutical company will continue with its development.
Gene therapy
Finally, an alternative approach to the problem has been reported utilizing the principles of gene therapy65. Plasmidcationic liposome-mediated human oal-antitrypsin gene transfer to a CF bronchial epithelial cell line has been achieved. It succeeded in protecting the cells from the toxic effects of elastase and inhibited elastase-stimulated release of neutrophil chemotactic activity from the epithelial cells. Whether this in vitro work can be translated into a clinical therapy remains to be seen.
CONCLUSIONS
Neutrophil-dominated inflammation is a major factor in CF lung disease. Much of the damage is due to the huge quantity of proteases, and in particular neutrophil elastase, which is released into the lungs. These proteolytic enzymes overwhelm the lungs' own antiprotease defences, alantiprotease and SLPI. Correcting this imbalance may well lead to a reduction in the consequences of chronic lung inflammation. Plasma-derived ac-antiprotease may be effective, but there are safety issues; the transgenic (sheep-derived) human cql-antitrypsin is undergoing safety trials and may prove to be of great benefit. Recombinant SLPI has also been showvn to be effective in an early study and further trials are needed. Finally, a range of synthetic oral agents is also being developed.
